Developmental outcomes following prenatal exposure to methamphetamine: A Western Australian perspective
- PMID: 31479558
- DOI: 10.1111/jpc.14618
Developmental outcomes following prenatal exposure to methamphetamine: A Western Australian perspective
Abstract
Aim: To describe neurodevelopmental outcomes among a cohort of Western Australian infants exposed to maternal methamphetamine use during pregnancy and to determine whether the Ages and Stages Questionnaire is a reliable screening tool for this population.
Methods: Methamphetamine-using women were approached for participation when referred to the state-wide perinatal specialist drug and alcohol service for pregnancy care. Drug use during pregnancy was self-reported in each trimester using a standardised questionnaire. Ages and Stages Questionnaires were completed by infant care givers at 4 and 12 months, and development was formally assessed at 12 months using the Griffiths Mental Development Scales. Griffiths results for term-born infants in our cohort were compared to a Western Australian historical cohort of 443 healthy 1-2-year-olds.
Results: A total of 112 methamphetamine-using pregnant women participated in the study, who gave birth to 110 live-born infants. Ages and Stages Questionnaires were completed for 89 (81%) and 78 (71%) of the infants at 4 and 12 months, respectively. The Ages and Stages assessment identified 30 infants (33.7%) as having a potential developmental delay at 4 months and 29 infants (38.7%) as having a potential developmental delay at 12 months. Griffiths assessments were performed on 64 (58%) of the infants, with a mean general quotient of 92.7. This was significantly lower in term-born babies compared to the historical cohort (who had a median general quotient of 113.0). There was a weak correlation between 12-month Ages and Stages scores and Griffiths general quotients (r = 0.322) and no correlation between 4-month Ages and Stages Questionnaire scores and later Griffiths results.
Conclusions: Infants born to women reporting methamphetamine use during pregnancy are at increased risk of developmental delay and may warrant enhanced developmental follow-up. However, they are a challenging group to follow due to complex psychosocial factors. Ages and Stages Questionnaires at 4 and 12 months were not helpful in screening for infants who had a developmental delay at 12 months.
Keywords: Ages and Stages Questionnaire; Griffiths Mental Development Scale; child development; developmental outcome; maternal drug use; methamphetamine.
© 2019 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
References
-
- The Therapeutic Goods Administration. Australian Register of Therapeutic Goods Australia. Canberra: The Administration; 2018. Available from: https://www.tga.gov.au/artg [accessed 22 June 2018].
-
- Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2016: Detailed Findings. Canberra: The Institute; 2017.
-
- Wright TE, Schuetter R, Tellei J, Sauvage L. Methamphetamines and pregnancy outcomes. J. Addict. Med. 2015; 9: 111-7.
-
- Dinger J, Hinner P, Reichert J, Rudiger M. Methamphetamine consumption during pregnancy - Effects on child health. Pharmacopsychiatry 2017; 50: 107-13.
-
- Burchfield DJ, Lucas VW, Abrams RM, Miller RL, DeVane CL. Disposition and pharmacodynamics of methamphetamine in pregnant sheep. JAMA 1991; 265: 1968-73.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical